UNIVERSITY OF SOUTH FLORIDA
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1956-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.usf.edu
The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2010-02-11
- Last Posted Date
- 2012-06-18
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 20
- Registration Number
- NCT01067573
- Locations
- 🇺🇸
USF Health, Tampa, Florida, United States
Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease
Phase 4
Completed
- Conditions
- Overactive Bladder in Parkinson's Disease
- Interventions
- Drug: placebo
- First Posted Date
- 2009-11-23
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 23
- Registration Number
- NCT01018264
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸University of Miami, Miami, Florida, United States
Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab
Phase 2
Completed
- Conditions
- Breast CancerCardiac Toxicity
- Interventions
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 468
- Registration Number
- NCT01009918
- Locations
- 🇺🇸
Illinois CancerCare - Havana, Havana, Illinois, United States
🇺🇸Saint Luke's Hospital, Chesterfield, Missouri, United States
🇺🇸Illinois CancerCare - Canton, Canton, Illinois, United States
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3
- First Posted Date
- 2009-10-09
- Last Posted Date
- 2012-06-18
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 20
- Registration Number
- NCT00992771
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸University of Florida, Gainesville, Florida, United States
🇺🇸University of California - Los Angeles, Los Angeles, California, United States
Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer
Phase 2
Terminated
- Conditions
- LeukemiaLymphomaMalnutritionMyelodysplastic SyndromesUnspecified Childhood Solid Tumor, Protocol SpecificWeight Changes
- Interventions
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 9
- Registration Number
- NCT00949117
Strategies To Prevent Pneumonia 2 (SToPP2)
Phase 2
Completed
- Conditions
- Ventilator-Associated PneumoniaMechanical Ventilation ComplicationInfections, Hospital
- Interventions
- Procedure: Pre-intubation CHXProcedure: Control
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2016-01-11
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 314
- Registration Number
- NCT00893763
- Locations
- 🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States
Videophone Administered Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder
Phase 2
Completed
- Conditions
- Obsessive Compulsive Disorder
- Interventions
- Behavioral: Wait-list controlBehavioral: Cognitive-behavioral therapy
- First Posted Date
- 2009-04-15
- Last Posted Date
- 2015-06-11
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 31
- Registration Number
- NCT00881465
- Locations
- 🇺🇸
University of South Florida, St. Petersburg, Florida, United States
Losartan in Treating Pulmonary Fibrosis in Patients With Stage I, II, or III Non-Small Cell Lung Cancer
Not Applicable
Withdrawn
- Conditions
- Pulmonary ComplicationsRadiation FibrosisDyspneaLung Cancer
- Interventions
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- University of South Florida
- Registration Number
- NCT00880386
Losartan in Treating Patients With Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 20
- Registration Number
- NCT00879879
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
D-Cycloserine Augmentation of Therapy for Pediatric Obsessive-Compulsive Disorder
Phase 2
Completed
- Conditions
- Obsessive-compulsive Disorder
- Interventions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2012-10-17
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 30
- Registration Number
- NCT00864123
- Locations
- 🇺🇸
University of South Florida, St. Petersburg, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath